ArticleFrontiers in oncology2025

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.

Maria T Bourlon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.